FONTEM-VENTURES
Fontem Ventures, owner of vapour brand blu, today calls on the World Health Organisation (WHO) to recognise the growing evidence that vaping can make a significant contribution to tobacco harm reduction, ahead of World No Tobacco Day 2019 on May 31st .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005659/en/
“Currently more than half the world’s population live in countries where vaping is either banned or exists in a regulatory grey area.” said Dr Nveed Chaudhary, Scientific & Regulatory Affairs Senior Manager at Imperial Brands, parent company of Fontem Ventures. “We believe the WHO could help by recognizing the science underlying tobacco harm reduction and the potential health benefits to millions of smokers by opening up new options to switch away from combustible tobacco.”
In countries like the US where vaping is recognised as an alternative for smokers, and vaping products are widely available, data shows smoking rates are falling rapidly1 .
“We are encouraged by China’s recent decision to create a products standards based regulatory framework for vaping2 , which would potentially enable hundreds of millions of smokers to access an alternative to combustible tobacco.” said Dr Chaudhary.
China, India and Indonesia combined have more than 430 million daily smokers, nearly 50% of the world’s total smoking population3 .
Article 1(d) of the WHO’s Framework Convention on Tobacco Control (FCTC) defines tobacco control as “a range of supply, demand and harm reduction strategies that aim to improve the health of a population by eliminating or reducing their consumption of tobacco products and exposure to tobacco smoke.”
E-vapour products contain no tobacco4 , and peer reviewed scientific evidence5 suggests that switching to e-vapour products will substantially reduce exposure to harmful toxicants6 found in combustible tobacco smoke.
About Fontem Ventures
Fontem
Ventures
BV, is the e-vapour business behind blu
.
Headquartered in Amsterdam, Fontem Ventures’ purpose is to drive
electronic vaping technology forward, delivering a better alternative to
smokers and vapers around the world. Fontem Ventures is a subsidiary of
Imperial Brands plc.
1
https://www.cnbc.com/2018/11/08/cdc-says-smoking-rates-fall-to-record-low-in-us.html
2
https://ecigintelligence.com/china-issues-new-industry-standards-for-e-cigarettes-and-e-liquids/
(Subscription only)
3
https://files.tobaccoatlas.org/wp-content/uploads/2018/03/TobaccoAtlas_6thEdition_LoRes.pdf
4
https://www.blu.com/en/US/explore/explore-vaping/e-liquid/what-is-an-eliquid.html
5
Article 14 The WHO FCTC states that “each Party shall develop and
disseminate appropriate, comprehensive and integrated guidelines based
on scientific evidence
and best practices, taking into account
national circumstances and priorities, and shall take effective measures
to promote cessation of tobacco use and adequate treatment for tobacco
dependence” The body of scientific evidence supporting the harm
reduction potential of vaping is now significant and a useful summary
can be found here: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf
6
http://www.fontemscience.com/research/library/evaluation-of-the-safety-profile-of-an-electronic-vapour-product-used-for-two-years-by-smokers-in-a-real-life-setting/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005659/en/
Contact:
Press Contact James Campbell Senior Communications Manager Fontem Ventures B.V. james.campbell@blu.com +31 61 442 6896
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
